Overview

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)

Status:
Not yet recruiting
Trial end date:
2026-05-12
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess is to evaluate the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme LLC